Seeing the good and bad in aplastic anemia: Is autoimmunity in AA dysregulated or antineoplastic?

Hematology Journal

Volumn 3, Issue 4, 2002, Pages 169-175

  Nissen, Catherine ^a   Schubert, Jörg ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Antineoplastic reactivity; Aplastic anemia; Autoimmunity

Indexed keywords

AUTOANTIGEN; IMMUNOSUPPRESSIVE AGENT;

ANTIGEN RECOGNITION; APLASTIC ANEMIA; APOPTOSIS; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BONE MARROW APLASIA; BONE MARROW HYPOPLASIA; CELL COMMUNICATION; CELL FUNCTION; CELL GROWTH; CELL POPULATION; CELL TRANSFORMATION; CLONAL ANERGY; CONTROLLED STUDY; CYTOLYSIS; DISEASE ACTIVITY; DISEASE SEVERITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; MOLECULAR CLONING; PREVALENCE;

ANEMIA, APLASTIC; APOPTOSIS; AUTOANTIGENS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; BONE MARROW CELLS; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; ERYTHROCYTES, ABNORMAL; GLYCOSYLPHOSPHATIDYLINOSITOLS; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOSUPPRESSIVE AGENTS; MEMBRANE PROTEINS; MODELS, IMMUNOLOGICAL; MYELODYSPLASTIC SYNDROMES; NOCTURNAL PAROXYSMAL DYSTONIA; TUMOR ESCAPE; TUMOR STEM CELLS;

EID: 0036381344     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200179     Document Type: Article

References (69)

1. Sieff CA, Nisbet-Brown E, Nathan DG. Congenital bone marrow failure syndromes. Br J Haematol 2000; 111: 30-42.
2. Nimer SD, Ireland P, Meshkinpour A, Franc M. An increased HLA DR2 frequency is seen in aplastic anemia patients. Blood 1994; 84: 323-327.
3. Kapustin SI, Popova TI, Lyshchov AA, Imyanitov EN, Blinov MN, Abdulkadyrov KM. HLA-DR4-Ala74 beta is associated with risk and poor outcome of severe aplastic anemia. Ann Hematol 2001; 80: 66-71.
4. Nagao T, Mauer AM. Concordance for drug-induced aplastic anemia in identical twins. N Engl J Med 1969; 281: 7-11.
5. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med 1997; 336: 1365-1372.
6. Young NS. Hematopoietic cell destruction by immune mechanisms in acquired aplastic anemia. Semin Hematol 2000; 37: 3-14.
7. Viollier R, Tichelli A. Predictive factors for cure after immunosuppressive therapy of aplastic anemia. Acta Haematol 2000; 103: 55-62.
8. Rao AN, Brown AK, Rieder RF, Clegg JB, Marsh WL: Aplastic anemia with fetallike erythropoiesis following androgen therapy. Blood 1978; 51: 711-719.
9. Piaggio G, Podesta M, Pitto A, Sessarego M, Figari O, Fugazza G, et al. Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy. Br J Haematol 1999; 107: 505-511.
10. Ishihara S, Nakakuma H, Kawaguchi T, Nagakura S, Horikawa K, Hidaka M, et al. Two cases showing clonal progression with full evolution from aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome to myelodysplastic syndromes and leukemia. Int J Hematol 2000; 72: 206-209.
11. Kudo S, Harigae H, Watanabe N, Takasawa N, Kimura J, Kameoka J, et al. Increased HbF levels in dysery-thropoiesis. Clin Chim Acta 2000; 291: 83-87.
12. Keung YK, Pettenati MJ, Cruz JM, Powell BL, Woodruff RD, Buss DH. Bone marrow cytogenetic abnormalities of aplastic anemia. Am J Hematol 2001; 66: 167- 171.
13. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci USA 1999; 96: 5209-5214.
14. Luzzatto L. Paroxysmal murine Hemoglobinuria(?): A model for human PNH. Blood 1999; 94: 2941-2944.
15. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253 - 1258.
16. Socie G, Mary JY, de Gramont A, Rio B, Leporrier M, Rose C et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet 1996; 348: 573-577.
17. Socie G, Rosenfeld S, Frickhofen N, Gluckman E, Tichelli A. Late clonal diseases of treated aplastic anemia. Semin Hematol 2000; 37: 91-101.
18. Wang H, Chuhjo T, Teramura M, Mizoguchi H, Nakao S. Relative increase of granulocytes with a paroxysmal nocturnal hemoglobinuria phenotype is a common feature of aplastic anemia at diagnosis. Blood 2000; 96: 231a.
19. Bessler M. Paroxysmal nocturnal hemoglobinuria: the price for a chance. Schiveiz Med Wochenschr 1996; 126: 1912 -1921.
20. Luzzatto L, Bessler M. The dual pathogenesis of paroxysmal nocturnal hemoglobinuria. Curr Opin Hematol 1996; 3: 101-110.
21. Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise? Cell 1997; 88: 1-4.
22. Karadimitris A, Manavalan JS, Thaler HT, Notaro R, Araten DJ, Nafa K et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood 2000; 96: 2613.
23. Karadimitris A, Luzzatto L. The cellular pathogenesis of paroxysmal nocturnal haemoglobinuria. Leukemia 2001; 15: 1148-1152.
24. Karadimitris A, Li K, Aruten DJ, Nafa K, Thertullien R, Stevens AE et al. A novel association of T-LGL leukemia and PNH supports the central role of a T-cell-mediated immune response in the pathogenesis of PNH. Blood 2000; 96: 233a.
25. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001; 112: 195-200.
26. Karadimitris A, Notaro R, Koehne G, Roberts IAG, Luzzatto L. PNH cells are as sensitive to T cell-mediated lysis as their normal counterparts: implications for the pathogenesis of Paroxysmal Nocturnal Haemoglobinuria. Br J Haematol 2000; 111: 1158-1163.
27. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14: 123-133.
28. Pende D, Cantoni C, Rivera P, Vitale M, Castriconi R, Marcenaro S et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur J Immunol 2001; 31: 1076-1086.
29. Atkins GJ, McQuaid S, Morris-Downes MM, Galbraith SE, Amor S, Cosby SL. Transient virus infection and multiple sclerosis. Rev Med Virol 2000; 10: 291-303.
30. Yoon JW, Jun HS. Cellular and molecular roles of beta cell autoantigens, macrophages and T cells in the pathogenesis of autoimmune diabetes. Arch Pharm Res 1999; 22: 437-441.
31. Nissen C, Tichelli A, Gratwohl A, Warthmann C, Moser Y, dalle Carbonare V et al. High incidence of transiently appearing complement-sensitive bone marrow precursor cells in patients with severe aplastic anemia-A possible role of high endogenous IL-2 in their suppression. Acta Haematol 1999; 101: 165-172.
32. Young NS, Maciejewski JP. Genetic and environmental effects in paroxysmal nocturnal hemoglobinuria: this little PIG-A goes 'Why? Why? Why? [comment]. J Clin Invest 2000; 106: 637-641.
33. Takami A, Nakao S, Tatsumi Y, Wang H, Weihua Z, Yamazaki H et al. High inducibility of heat shock protein 72 (hsp72) in peripheral blood mononuclear cells of aplastic anaemia patients: a reliable marker of immune-mediated aplastic anaemia responsive to cyclosporine therapy. Br J Haematol 1999; 106: 377-384.
34. Nakao S, Zeng WH, Murata R, Kondo Y. Identification of a novel antigen derived from hematopoietic progenitor cells that is recognized by the immune system of a patient with aplastic anemia. Blood 1999; 94: 193a.
35. Hirano N, Schultze JL, Butler MO, Guinan EC. Identification of kinektin as a target antigen in immune-mediated aplastic anemia. Blood 1999; 94: 193a.
36. Zeng W, Maciejcwski JP, Chen G, Young NS. Limited heterogeneity of T cell receptor BV usage in aplastic anemia. J Clin Invest 2001; 108: 765-773.
37. Marsh JC, Geary CG. Is aplastic anaemia a pre-leukaemic disorder? Br J Haematol 1991; 77: 447-452.
38. Barrett J. Myelodysplastic syndrome and aplastic anemia- diagnostic and conceptual uncertainties. Leuk Res 2000; 24: 595-596.
39. Marsh JC, Hows JM, Bryett KA, Al-Hashimi S, Fairhead SM, Gordon-Smith EC. Survival after antilymphocyte globulin therapy for aplastic anemia depends on disease severity. Blood 1987; 70: 1046-1052.
40. Hattori H, Machii T, Ueda E, Shibano M, Kageyama T, Kitani T. Increased frequency of somatic mutations at glycophorin A loci in patients with aplastic anaemia, myelodysplastic syndrome and paroxysmal nocturnal haemoglobinuria. Br J Haematol 1997; 98: 384-391.
41. Chen R, Eshleman JR, Brodsky RA, Medof ME. Glycophosphatidylinositol-anchored protein deficiency as a marker of mutator phenotypes in cancer. Cancer Res 2001; 61: 654-658.
42. Lyakisheva A, Felda O, Ganser A, Schmidt RE, Schubert J. Paroxysmal nocturnal hemoglobinuria-differential gene expression of EGR-1 and TAXREB107. Exp Hematol 2002; 30: 18-25.
43. Stafford HA, Nagarajan S, Weinberg JB, Medof ME. PIG-A, DAF and proto-oncogene expression in paroxysmal nocturnal haemoglobinuria-associated acute myelogenous leukaemia blasts. Br J Haematol 1995; 89: 72-78.
44. Mortazavi Y, Tooze JA, Gordon-Smith FC, Rutherford TR. N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. Blood 2000; 95: 646-650.
45. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M et al. Hematopoietic stem cell quiescence maintained by p2lcipl/wafl. Science 2000; 287: 1804-1808.
46. Chen R, Nagarajan S, Prince GM, Maheshwari U, Terstappen LW, Kaplan DR et al. Impaired growth and elevated fas receptor expression in PIGA(+) stem cells in primary paroxysmal nocturnal hemoglobinuria. J Clin Invest 2000; 106: 689-696.
47. Issaragrisil S, Piankijagum A, Chinprasertsuk S, Kruatrachue M. Growth of mixed erythroid-granulocytic colonies in culture derived from bone marrow of patients with paroxysmal nocturnal hemoglobinuria without addition of exogenous stimulator. Exp Hematol 1986; 14: 861-866.
48. Iwamoto N, Kawaguchi T, Horikawa K, Nagakura S, Kagimoto T, Suda T et al. Preferential hematopoiesis by paroxysmal nocturnal hemoglobinuria clone engrafted in SCID mice. Blood 1996; 87: 4944-4948.
49. Nissen C, Genitsch A, Sendelov S, Dalle Carbonare V, Wodnar-Filipowicz A. Cell cycling stress in the monocyte line as a risk factor for progression of the aplastic anaemia/paroxysmal nocturnal haemoglobinuria syndrome to myelodysplastic syndrome. Acta Haematol 2000; 103: 33-40.
50. Krishnaraju K, Hoffman B, Liebermann DA. The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells. Blood 1998; 92: 1957-1966.
51. Krishnaraju K, Hoffman B, Liebermann DA. Early growth response gene 1 stimulates development of hematopoietic progenitor cells along the macrophage lineage at the expense of the granulocyte and erythroid lineages. Blood 2001; 97: 1298-1305.
52. Brodsky RA, Vala MS, Barber JP, Medof ME, Jones RJ. Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci USA 1997; 94: 8756-8760.
53. Horikawa K, Nakakuma H, Kawaguchi T, Iwamoto N, Nagakura S, Kagimoto T et al. Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome. Blood 1997; 90: 2716-2722.
54. Ware RE, Nishimura J, Moody MA, Smith C, Rosse WF, Howard TA. The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood 1998; 92: 2541-2550.
55. Bastisch I, Tiede A, Deckert M, Ziolek A, Schmidt RE, Schubert J. Glycosylphosphatidylinositol (GPI)-deficient Jurkat T cells as a model to study functions of GPI-anchored proteins. Clin Exp Immunol 2000; 122: 49-54.
56. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood 2001; 97: 895-900.
57. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol 1995; 91: 245-252.
58. Killick SB, Cox CV, Marsh JC, Gordon-Smith EC, Gibson FM. Mechanisms of bone marrow progenitor cell apoptosis in aplastic anaemia and the effect of anti-thymocyte globulin: examination of the role of the Fas-Fas-L interaction. Br J Haematol 2000; 111: 1164-1169.
59. Rosenfeld C, List A. A hypothesis for the pathogenesis of myelodysplastic syndromes: implications for new therapies. Leukemia 2000; 14: 2-8.
60. Novitzky N, Mohamed R, Finlayson J, du Toit C. Increased apoptosis of bone marrow cells and preserved proliferative capacity of selected progenitors predict for clinical response to anti-inflammatory therapy in myelodysplastic syndromes. Exp Hematol 2000; 28: 941-949.
61. Parker JE, Mufti GJ. The role of apoptosis in the pathogenesis of the myelodysplastic syndromes. Int J Hematol 2001; 73: 416-428.
62. Merchant SH, Gonchoroff NJ, Hutchison RE. Apoptotic index by Annexin V flow cytometry: adjunct to morphologic and cytogenetic diagnosis of myelodysplastic syndromes. Cytometry 2001; 46: 28-32.
63. Reines BP. Bystanders or bad seeds? Many autoimmune-target cells may be transforming to cancer and signalling 'danger' to the immune system. Autoimmunity 2001; 33: 121-134.
64. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37: 15-29.
65. Suvajdzic N, Marisavljevic D, Jovanovic V, Pantic M, Sefer D, Colovic M. Pure red cell aplasia evolving through the hyperfibrotic myelodysplastic syndrome to the acute myeloid leukemia: some pathogenetic aspects. Hematol Cell Ther 1999; 41: 27-29.
66. Horikawa K, Kawaguchi S, Ishihara S, Nagakura S, Hidaka M, Mitsuya H et al. Frequent detection of HPRT gene mutations in paroxysmal nocturnal hemoglobinuria. Blood 2000; 96: 232a.
67. Nishimura J, Kanakura Y, Ware RE, Shichishima T, Nakakuma H, Ninomiya H et al. Serial analysis of clonal expansion in PNH by flow cytometry. Blood 2000; 96: 231a.
68. Hirota T, Nishimura J, Kuwamaya M, Machii T, Kinoshita T, Kanakura Y. Quantitative and qualitative changes in PNH clonal expansion over time. Blood 2000; 96: 231a.
69. Araten DJ, Swirsky D, Karadimitris A, Notaro R, Nafa K, Bessler M, et al. Cytogenctic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol 2001; 115: 360-368.